## External reviewers

<table>
<thead>
<tr>
<th>Invited professional associations</th>
<th>Reviewers</th>
</tr>
</thead>
</table>
| Belgian Society of Medical Oncology * | Dr. Gino Pelgrims  
Dr. Aldrik Nielander |
| Royal Belgian Radiological Society ** | Prof. dr. Bart Op de Beeck |
| The Belgian Association of Clinical Cytology ** | Prof. dr. John-Paul Borgers |
| Vlaamse Vereniging voor Obstetrie en Gynaecologie ** | Dr. Koen Traen |
| Groupement des Gynécologues Obstétriciens de Langue Français de Belgique ** | Dr. Michel Coibion |
| Belgische Vereniging voor Radiotherapie-Oncologie - Association Belge de Radiothérapie *** | - |
| Belgian Society of Pathology **** | - |
| Domus Medica **** | - |
| Société Scientifique de Médecine Générale **** | - |

* Two experts assigned and feedback received.  
*** Two experts assigned, but one feedback received.  
**One or two experts assigned, but no feedback received.  
****No experts assigned
VULVAR-VAGINAL CANCER

- Vulvar-vaginal cancer guidelines expert panel
- External reviewers
- Table of contents
- National guidelines vulvar-vaginal cancer (Full text)
  - Introduction
  - Search for evidence
  - External review
  - Epidemiology
  - Histological types and five-year survival
  - Vulvar intra-epithelial neoplasia (VIN)
    - Diagnosis
    - Treatment
    - Follow-up
- Invasive vulvar cancer
  - Screening
  - Diagnosis and staging
  - Treatment of stage I FIGO 2009
  - Treatment of stage II & III FIGO 2009
  - Treatment of stage IV FIGO 2009
  - Follow-up
  - Treatment of recurrent disease
- Vulvoperineal Paget's disease
- Vaginal intraepithelial neoplasia (VAIN) and invasive vaginal carcinoma
  - Vaginal intraepithelial neoplasia (VAIN)
  - Invasive vaginal cancer
- References
- Appendix 1: FIGO-2009 vulvar carcinoma
INTRODUCTION

This document provides an overview of the clinical practice guidelines for vulvar and vaginal cancer. They are developed by a panel of experts (see 'expert panel') comprising clinicians of different specialties and were reviewed by relevant professional associations (see 'external reviewers').

The guidelines are based on the best evidence available at the time they are derived (date restriction early 2010). The aim of these guidelines is to assist all care providers involved in the care of patients with vulvar cancer.

The guidelines presented cover screening, diagnosis, treatment and follow up of vulvar and vaginal cancer.

SEARCH FOR EVIDENCE

Sources

The guidelines are adapted from the guidelines of the Flemish Society for Obstetrics and Gynaecology (Flemish Gynaecological Oncology Group) which were revised in September 2008. They are based on existing clinical trials and international guidelines and a broad search on Medline.

Level of evidence

A level of evidence was assigned to each recommendation:

- Level A: randomized studies, prospective cohort study
- Level B: retrospective cohort study with consistent protocol, case-control studies, extrapolations from level A studies
- Level C: case-series or extrapolations from level B studies
- Level D: expert opinion

EXTERNAL REVIEW

The guidelines prepared by the expert panel were circulated to the relevant professional associations (see 'external reviewers'). Each association was asked to assign two key persons to discuss the recommendations during an open meeting. As a preparation of the meeting all invited reviewers were asked to score each recommendation on a 5-point Likert-scale to indicate their agreement with the recommendation, with a score of ‘1’ indicating ‘completely disagree’, ‘2’ indicating ‘somewhat disagree’, ‘3’ indicating ‘unsure’, ‘4’ indicating ‘somewhat agree’, and ‘5’ indicating ‘completely agree’ (it was also possible to answer ‘not applicable’ in case they were not familiar with the underlying evidence). All scores were then summarized into a mean score and % of ‘agree’-scores (score ‘4’ and ‘5’) to allow a targeted discussion. The recommendations were then discussed during a face-to-face meeting on April 21st 2010. Based on this discussion a final draft of the guidelines was prepared, and discussed by the expert panel by email.
EPIDEMIOLOGY

In Belgium, 162 new cases of vulvar carcinoma and 45 new cases of vaginal carcinoma were reported in 2006 [1]. Traditionally vulvar pre-invasive and invasive pathology affects postmenopausal women, although younger women can be diagnosed with this condition, often based on HPV infection.

The vulvar intra-epithelial neoplasia (VIN) among young women is related to an HPV infection and is also more common in smokers. In contrast, in older women VIN usually develops in dystrophic lesions (lichen sclerosus and atrophicus). Because of these different etiopathogenesis lesions among young women are more frequently multifocal while older women have more frequently a unifocal lesion.

HISTOLOGICAL TYPES AND FIVE-YEAR SURVIVAL

Histological types

Epithelial carcinoma
- Vulvar intra-epithelial neoplasia (VIN)
  - Squamous type with or without koilocytosis
  - Non-squamous type
    - Morbus Paget
    - Melanoma in situ
- Invasive vulvar carcinoma
  - Invasive squamous carcinoma
    - Superficial invasive squamous carcinoma

Invasive melanoma

Mesenchymal tumors

Five-year survival [2]

<table>
<thead>
<tr>
<th>Stage</th>
<th>Occurrence</th>
<th>5-year survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>34%</td>
<td>78%</td>
</tr>
<tr>
<td>II</td>
<td>28%</td>
<td>59%</td>
</tr>
<tr>
<td>III</td>
<td>26%</td>
<td>43%</td>
</tr>
<tr>
<td>IV</td>
<td>8%</td>
<td>11%</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>59%</td>
</tr>
</tbody>
</table>

VULVAR INTRA-EPITHELIAL NEOPLASIA (VIN)

Diagnosis

- A biopsy of a clinically suspicious lesion should be taken under vulvascopy including the anal region (evidence level D).
- As CIN is associated with VIN a cervical cytology should be performed (evidence level C).
- The International Society for the Study of Vulvar Disease (ISSVD)
VULVAR-VAGINAL CANCER

INVASIVE VULVAR CANCER

Screening

- No evidence for screening (evidence level D).

Diagnosis and staging

- A detailed history including family and personal history should be taken (evidence level D).
- A complete clinical examination including gynaecological examination should be done (evidence level D).
- The following pre-operative examinations should be performed:
  - Biochemical studies
    - Preoperative blood test (evidence level D)
    - Serum tumormarkers: squameus cell cancer antigen (SCCA) can be considered (evidence level D)
  - Vulvoscopy with biopsy for histological confirmation (evidence level D).
  - Cervical cytology(evidence level D).
  - Abdominal and pelvic CT (evidence level D).
  - MRI can be considered in advanced cases, for instance anal or urethral invasion (evidence level D).
  - PET/CT can be considered in case of suspicious inguinofemoral lymph nodes (evidence level D).
  - (Pre-operative) Chest X-ray (evidence level D).
  - FNAC or core biopsy in case of suspicious inguinal lymph nodes should be considered (evidence level D).
  - Other examinations (e. g. cystoscopy, rectoscopy) as clinically indicated (evidence level D).

Treatment

- In case of flat condyloma or HPV effect a wait and see attitude is recommended (evidence level D).
- Excision of the lesion or laser vaporisation is recommended in case of VIN usual type and differentiated type (evidence level D) [3].
- In case of section margins involved by VIN only a wait and see policy is recommended (evidence level D).

Follow-up

- Clinical examination and optionally vulvar cytology should be performed every 6 months in the first two years after excision. Further follow-up will depend on the results. Vulvoscopy on indication (evidence level D).
• For the classification of invasive vulvar cancer the FIGO-2009 classification is recommended (evidence level D) (see appendix 1).
• The histopathological report should describe the following:
  o Histological type
  o Grade of differentiation
  o Maximal diameter
  o Depth of the stromal invasion
  o Minimal free resection margin (mm)
  o Surgical margins
  o Lymphovascular involvement
  o Presence associated VIN lesions
  o Number of positive lymph nodes and total number of lymph nodes removed

Treatment of stage I FIGO-2009

• In case of stage Ia a wide local excision (partial vulvectomy) without lymphadenectomy is recommended (evidence level C). A pathological resection margin of > 8mm should be obtained (clinically 1 to 2 cm) (evidence level C).
• In case of stage Ib a partial (or hemi) vulvectomy should be performed (evidence level C). A pathological resection margin of > 8mm should be obtained (clinically 1 to 2 cm) (evidence level C).
• In case of multifocal lesions a total vulvectomy is recommended (evidence level C).
• In stage Ib a sentinel procedure of the inguinofemoral lymph nodes is recommended, if the tumor is less than 4 cm and not multifocal. In case of central lesions a bilateral sentinel procedure is needed (evidence level A) [3].
• In case of positive sentinel a bilateral inguinofemoral lymphadenectomy is needed (evidence level B) [4].
• For the tumors larger than 4 cm or multifocal a complete unilateral or bilateral inguino-femoral lymphadenectomy should be performed. In case of lateral lesions a unilateral lymphadenectomy is recommended. In case of central lesions a bilateral lymphadenectomy is needed (evidence level B) [3,4].

Treatment of stage II & III FIGO-2009

• Preoperative platinum based chemotherapy or (chemo)radiotherapy can be considered (evidence level C).
• In case of stage II a total or partial vulvectomy with bilateral inguinofemoral lymphadenectomy should be performed (evidence level C). A pathological resection margin of > 8mm should be obtained (clinically 1 to 2 cm) (evidence level C).
• In case of stage III a total or partial vulvectomy with bilateral inguinofemoral lymphadenectomy should be performed (evidence level C). A pathological resection margin of > 8mm should be obtained (clinically 1 to 2 cm) (evidence level C).
• In case of anal extension treatment as recommended for stage IV should be performed (evidence level C).
• Postoperative vulvar radiotherapy (optionally with concomitant platinum based chemotherapy) is considered in the following cases (evidence level D):
  o Lesions of > 4cm diameter
  o Microscopic resection margin < 8mm
  o Evidence of extensive lymphovascular involvement
• Postoperative radiotherapy (optionally with concomitant chemotherapy) of the inguinofemoral and external iliacal lymph nodes is recommended.
in the following cases (evidence level D):
  o Macroscopic metastatic inguinofemoral lymph nodes
  o > 2 microscopically affected lymph nodes

Treatment of stage IV FIGO-2009

- Radiotherapy is recommended in case of stage IVA (evidence level C). Concomitant cisplatin should be considered (evidence level D).
- Alternatively neoadjuvant chemotherapy followed by surgery or radiotherapy can be considered (evidence level C).
- According to the response sequential exenterative surgery (response < 75% after 45 Gy) can be considered (evidence level C). In case of complete response a total dose of 60 Gy is recommended. In case of partial response a total dose of 65 Gy is recommended (evidence level D).
- Treatment with platinum based chemotherapy (in combination with paclitaxel or gemcitabine) with palliative intent can be considered in case of stage IVB (evidence level D).

Follow-up

- Follow-up consultations every 3 months in the first two years, every 6 months until 5 years after diagnosis, and every year after 5 years (evidence level D).
- Clinical examination is recommended at every follow-up consultation. Vulvar cytology might be considered (evidence level D).
- Routine imaging examinations to screen for distant recurrent disease are not recommended (evidence level D).

Treatment of recurrent disease

- In case of a solitary metastases surgical resection and/or (platinum based chemo)radiotherapy should be considered (evidence level C).
- In case of local recurrence in a previously irradiated region exenterative surgery can be considered in selected cases (evidence level C).
- Treatment with platinum based chemotherapy (in combination with paclitaxel or gemcitabine) with palliative intent can be considered (evidence level C).

VULVOPERINEAL PAGET'S DISEASE

- Vulvoperineal Paget's disease is a malignant epithelial neoplasm characterized by growth of adenocarcinoma cells within the epidermis of the vulva or perineum.
- Paget's disease is often multifocal or extending subepidermal underneath normal looking skin (evidence level D).
- A biopsy of a clinically suspicious lesion should be taken (evidence level D).
- A vulvoscopy should be performed (evidence level D).
- Wide excision or radiotherapy should be performed. Paget's disease is very radiosensitive. Local electron or 4-field photon field including wide margins should be performed (evidence level D).
VAGINAL INTRAEPITHELIAL NEOPLASIA (VAIN) AND INVASIVE VAGINAL CARCINOMA

Vaginal intraepithelial neoplasia

- VAIN is defined as preinvasive squamous cell carcinoma limited to the vaginal epithelium.
- A biopsy of a clinically suspicious lesion should be taken (*evidence level D*).
- A colposcopy should be performed in the following cases (*evidence level D*):
  - A Pap smear showing dysplasia
  - A normal Pap smear but with contact bleedings
  - Follow-up of a treated VAIN
  - Every macroscopic suspicious lesion irrespective of the cytology
- VAIN can be treated with local excision, or ablation or vaporisation. In case of multifocal lesions a local treatment with 5-FU can be considered (*evidence level C*).

Invasive vaginal cancer

- Tumors of the upper half of the vagina are treated like cervical carcinoma (*see guidelines cervical cancer*).
- Tumors of the lower half of the vagina are treated like vulvar carcinoma (*see guidelines invasive vulvar cancer*).
References

### FIGO Staging 2009 (surgical staging)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Tumor confined to the vulva or vulva and perineum</td>
<td></td>
</tr>
<tr>
<td>Ia</td>
<td>Tumour ≤ 2cm with stromal invasion of ≤ 1mm</td>
<td></td>
</tr>
<tr>
<td>Ib</td>
<td>Tumour &gt; 2cm with stromal invasion of &gt; 1mm</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Tumor with extension to adjacent perineal structures: lower third urethra, lower third vagina, anus</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Stage I or II tumour with spread to the lymph nodes</td>
<td></td>
</tr>
<tr>
<td>IIIa</td>
<td>A single lymph node ≥ 5 mm OR 1 or 2 lymph nodes &lt; 5 mm</td>
<td></td>
</tr>
<tr>
<td>IIIb</td>
<td>3 or more lymph nodes &lt; 5 mm OR 2 or more lymph nodes ≥ 5 mm</td>
<td></td>
</tr>
<tr>
<td>IIIc</td>
<td>Lymph nodes with extracapsular spread</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>Tumor with extension to the following structures: upper 2/3 urethra, upper 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone OR fixed or ulcerated regional lymph node metastasis</td>
<td></td>
</tr>
<tr>
<td>IVa</td>
<td>Distant metastasis (including pelvic lymph node metastasis)</td>
<td></td>
</tr>
</tbody>
</table>